| Friedland, Barbara |
NCT05128136: A Crossover Study Evaluating 3 Non-medicated Silicone IVRs |
|
|
| Completed | N/A | 48 | US | Impact of ring size on adherence | Population Council, Albert Einstein College of Medicine, Emory University | Hiv, Pregnancy Related | 12/22 | 01/23 | | |
NCT04778514: A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention |
|
|
| Completed | N/A | 30 | RoW | Dual Prevention Pill, DPP, PrEP and combined oral contraceptive (COC) as two separate tablets, Truvada, Zinnia F | Population Council, University of Zimbabwe | HIV Infections, Contraception | 09/23 | 09/23 | | |
NCT04778527: A Crossover Adherence and Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention |
|
|
| Active, not recruiting | N/A | 96 | RoW | Dual Prevention Pill, DPP, PrEP tablet and a COC as two separate tablets, Truvada, Zinnia F | Population Council | HIV Infections | 01/24 | 01/24 | | |
| Mgodi, Nyaradzo |
PALISADE, NCT06134362: Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) |
|
|
| Recruiting | 3 | 3500 | RoW | CAB LA, Apretude, CAB LA for PrEP | ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP | HIV Infections | 06/28 | 06/28 | | |
| Completed | 2/3 | 14232 | RoW | Moderna mRNA-1273, Vaccine 3 Dose, Vaccine 2 Dose | COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa | SARS-CoV-2 Infection, HIV Infections, COVID-19 | 04/24 | 04/24 | | |
| Completed | 2 | 330 | RoW | emtricitabine/tenofovir alafenamide, Descovy, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Truvada | Eastern Virginia Medical School, CONRAD, FHI 360, United States Agency for International Development (USAID), Gilead Sciences | Acceptability of Health Care, Adherence, Medication | 12/23 | 07/24 | | |
| Recruiting | 1 | 100 | US, RoW | Placebo Intravaginal Ring A, Placebo Intravaginal Ring B | University of Pittsburgh, United States Agency for International Development (USAID), Oak Crest Institute of Science | Safety, Acceptability | 02/25 | 12/25 | | |
NCT06046053: MATRIX-002: Trial to Assess Acceptability and Safety of Two Placebo Vaginal Films |
|
|
| Completed | 1 | 100 | US, RoW | Placebo Vaginal Film with Square Corners, Placebo Vaginal Film with Rounded Corners | Rohan, Lisa, PhD, United States Agency for International Development (USAID) | Safety, Acceptability, Usability | 12/24 | 12/24 | | |
INSIGHT, NCT05746065: A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women |
|
|
| Completed | N/A | 3087 | RoW | PrEP, Truvada | University of Washington, Bill and Melinda Gates Foundation | HIV Infections | 08/23 | 08/23 | | |
NCT04778514: A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention |
|
|
| Completed | N/A | 30 | RoW | Dual Prevention Pill, DPP, PrEP and combined oral contraceptive (COC) as two separate tablets, Truvada, Zinnia F | Population Council, University of Zimbabwe | HIV Infections, Contraception | 09/23 | 09/23 | | |
| Dandadzi, Adlight |
| Completed | 2 | 330 | RoW | emtricitabine/tenofovir alafenamide, Descovy, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Truvada | Eastern Virginia Medical School, CONRAD, FHI 360, United States Agency for International Development (USAID), Gilead Sciences | Acceptability of Health Care, Adherence, Medication | 12/23 | 07/24 | | |
NCT04778514: A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention |
|
|
| Completed | N/A | 30 | RoW | Dual Prevention Pill, DPP, PrEP and combined oral contraceptive (COC) as two separate tablets, Truvada, Zinnia F | Population Council, University of Zimbabwe | HIV Infections, Contraception | 09/23 | 09/23 | | |
